Multiple sclerosis treatment is entering a new era of hope. While there is no cure for this chronic autoimmune disease, a growing arsenal of therapies can significantly slow disease progression, reduce relapses, and help people maintain their quality of life for decades.

Living with a Manageable Condition

Multiple sclerosis treatment has transformed dramatically over recent decades. When someone receives an MS diagnosis today, they face a fundamentally different outlook than patients did even twenty years ago. The goals of treatment center on controlling disease activity, preventing permanent damage to the nervous system, and managing symptoms that affect daily life. Treatment effectiveness depends heavily on when therapy begins—the earlier, the better—as well as on the type and severity of the disease.^[1]

The approach to treating multiple sclerosis recognizes that this is not a one-size-fits-all condition. Some people experience periodic flare-ups followed by periods of remission, while others face a more gradual worsening of symptoms over time. Medical societies around the world have developed treatment guidelines based on extensive research, and doctors now have access to more than twenty approved medications to modify the course of the disease. At the same time, researchers continue exploring promising new therapies in clinical trials, offering additional hope for even better treatments in the future.^[6]

Treatment is not just about medications. It encompasses a comprehensive strategy that addresses the physical, emotional, and practical challenges of living with MS. Healthcare professionals work together as a team—neurologists, physical therapists, occupational therapists, psychologists, and nurses—to create personalized care plans that adapt as the disease and patient needs change over time.^[3]

Standard Treatment Approaches

The foundation of MS treatment rests on three pillars: disease-modifying therapies to slow the condition’s progression, treatments for acute relapses, and symptom management strategies. Each plays a crucial role in helping people maintain their independence and quality of life.^[9]

Disease-Modifying Therapies

Disease-modifying therapies, often abbreviated as DMTs, are medications designed to reduce the frequency and severity of relapses, prevent new areas of inflammation from forming in the brain and spinal cord, and slow the accumulation of disability. Most neurologists recommend starting a DMT as soon as possible after diagnosis because protecting the nervous system early can prevent irreversible damage. These medications work by modulating or suppressing the immune system, which mistakenly attacks the protective covering around nerve fibers in people with MS.^[8]

One category of disease-modifying drugs includes interferons, which are naturally produced proteins that help regulate the immune system’s response. Beta interferons, such as interferon beta-1a and interferon beta-1b, have been used for decades and are typically given by injection under the skin or into muscle. They work by altering how white blood cells respond to infections and reducing inflammation in the central nervous system. While effective, interferons can cause flu-like symptoms after injection, which usually diminish over time.^[10]

Another injectable medication is glatiramer acetate, a synthetic protein that resembles myelin, the protective coating around nerves that MS damages. By mimicking myelin, this medication appears to divert the immune system’s attack away from the actual myelin in the brain and spinal cord. Glatiramer acetate is given as a daily or three-times-weekly injection and has a favorable safety profile, though it may cause temporary skin reactions at injection sites.^[10]

Oral disease-modifying therapies have become increasingly popular because they eliminate the need for injections. Teriflunomide is a once-daily pill that helps prevent immune cells from rapidly multiplying and causing inflammation. Research has shown it can reduce the risk of conversion to clinically definite MS by 43% in people who have experienced their first episode of neurological symptoms suggestive of MS. Another oral medication, dimethyl fumarate, appears to protect nerve cells from oxidative stress and inflammation. Fingolimod works by trapping certain immune cells in lymph nodes so they cannot travel to the brain and spinal cord to cause damage.^[11]

For more aggressive forms of MS or when first-line therapies are not adequately controlling disease activity, doctors may recommend higher-efficacy treatments. Natalizumab is an antibody given by intravenous infusion once every four weeks. It works by preventing immune cells from crossing into the brain and spinal cord, where they would otherwise cause inflammation and damage. While highly effective at reducing relapses and new lesions visible on MRI scans, natalizumab requires careful monitoring because of a rare but serious risk of brain infection in some patients.^[8]

Mitoxantrone is an immunosuppressant medication approved for secondary progressive MS, progressive relapsing MS, and worsening relapsing-remitting MS. It works by suppressing the immune system broadly, but its use is limited to two to three years because of potential heart toxicity and increased cancer risk with cumulative doses. For this reason, it is typically reserved for people with aggressive disease who have not responded to other treatments.^[11]

A newer class of highly effective medications targets B cells, which are immune cells that play an important role in MS. Research has shifted away from viewing MS purely as a T-cell-mediated disease to recognizing that B cells have a key role in the disease process. Anti-CD20 monoclonal antibodies, including medications such as ocrelizumab and rituximab, selectively deplete B cells and have shown remarkable efficacy in reducing relapses and slowing disease progression. These are given by intravenous infusion every six months after initial loading doses. Ocrelizumab is the first medication approved specifically for primary progressive MS, a form of the disease that historically had no effective treatments.^[8]

Treatment Duration and Monitoring

Disease-modifying therapies are typically taken indefinitely, as long as they continue to control disease activity and are well tolerated. Doctors monitor patients regularly with neurological examinations and periodic MRI scans to assess whether the treatment is working effectively. Blood tests are also performed to watch for side effects on the liver, blood cells, and immune system. If a medication stops working adequately or causes unacceptable side effects, the treatment plan can be adjusted by switching to a different disease-modifying therapy.^[6]

Treating Acute Relapses

When someone with MS experiences a relapse—also called an exacerbation, flare-up, or attack—new neurological symptoms appear or existing symptoms suddenly worsen. Relapses typically develop over hours to days and can last from several days to several months before subsiding. The first-line treatment for moderate to severe relapses is high-dose corticosteroids, usually given intravenously over three to five days. Methylprednisolone is the most commonly used steroid for this purpose.^[9]

Corticosteroids work by powerfully reducing inflammation in the central nervous system, which can shorten the duration of a relapse and lessen its severity. Some doctors prescribe an equivalent high-dose oral steroid regimen as an alternative to intravenous treatment. While steroid treatment helps manage the immediate crisis of a relapse, it does not appear to affect the long-term course of the disease. Not every relapse requires steroid treatment—mild relapses that do not significantly impact daily functioning are often managed with symptom-relief strategies alone.^[9]

Side effects from short courses of high-dose steroids can include trouble sleeping, increased appetite, mood changes, elevated blood sugar, fluid retention, and stomach upset. These effects are generally temporary and resolve after the steroid course is completed. For people with diabetes or certain other medical conditions, doctors monitor closely during steroid treatment.^[4]

Managing Symptoms

Multiple sclerosis can cause a wide array of symptoms that vary greatly from person to person. Symptom management is an essential part of comprehensive MS care, addressing issues that affect comfort, function, and quality of life. Many symptoms can be effectively treated with medications, therapies, and lifestyle modifications.^[9]

Fatigue is one of the most common and debilitating symptoms of MS, affecting as many as 80% of people with the condition. It often feels different from ordinary tiredness—more overwhelming and not necessarily related to physical exertion. Treatment approaches include energy conservation techniques, regular exercise, adequate sleep, and sometimes medications that promote wakefulness. Physical and occupational therapy can help people learn strategies to manage daily activities more efficiently.^[3]

Muscle spasticity, stiffness, and spasms affect many people with MS. These can range from mild tightness to severe, painful muscle contractions. Oral muscle relaxants such as baclofen and tizanidine are commonly prescribed. For severe spasticity that does not respond to oral medications, doctors may recommend botulinum toxin injections directly into affected muscles or an implanted pump that delivers baclofen continuously into the spinal fluid. Physical therapy, stretching exercises, and sometimes complementary approaches like massage or acupuncture can also provide relief.^[4]

Bladder and bowel problems are common in MS and can significantly impact quality of life. Issues include urinary urgency, frequency, incomplete emptying, and incontinence. Various medications can help with bladder control, and learning pelvic floor exercises or intermittent self-catheterization techniques can be beneficial. For constipation, dietary modifications emphasizing fiber, adequate fluid intake, and sometimes laxatives or stool softeners are recommended.^[4]

Pain affects many people with MS and can take different forms, including nerve pain (burning, tingling, or stabbing sensations), muscle pain from spasticity, and headaches. Anticonvulsant medications such as gabapentin and pregabalin are often used for nerve pain. Anti-inflammatory drugs may help with musculoskeletal pain. Some people find relief through physical therapy, acupuncture, or relaxation techniques.^[11]

Depression and anxiety are more common in people with MS than in the general population. Whether this is due to the emotional impact of living with a chronic disease, changes in the brain from MS itself, or both is not fully understood. Psychotherapy, particularly cognitive behavioral therapy, can be very helpful. Antidepressant medications are also effective for many people. Building a strong support network, joining support groups, and maintaining social connections all contribute to emotional well-being.^[13]

Cognitive changes, including problems with memory, attention, information processing, and multitasking, affect approximately half of people with MS at some point. Cognitive rehabilitation—a type of therapy that teaches compensatory strategies and exercises to strengthen thinking skills—can help. Practical accommodations at work or home, such as using calendars, reminder apps, and written lists, can make daily life easier.^[4]

Treatment in Clinical Trials

While approved treatments have dramatically improved outcomes for people with MS, researchers continue working to develop even more effective therapies with fewer side effects. Clinical trials are carefully designed studies that test new medications, new uses for existing medications, and innovative treatment approaches before they become widely available. Participating in a clinical trial can give eligible patients access to cutting-edge therapies while contributing to scientific knowledge that will benefit future generations of people with MS.^[6]

Understanding Clinical Trial Phases

Clinical trials progress through several phases, each with a different purpose. Phase I trials focus primarily on safety. Researchers test a new treatment in a small group of people, usually 20 to 80 volunteers, to evaluate what dose is safe, identify side effects, and understand how the body processes the drug. These early studies provide crucial information about whether it is safe to proceed with larger trials.^[2]

Phase II trials expand testing to a larger group, typically several hundred participants. The primary goal is to evaluate whether the treatment is effective—does it reduce relapses, slow disease progression, or decrease the number of new lesions visible on MRI scans? Phase II trials also continue monitoring safety and side effects in a more diverse patient population. If results are promising, the treatment moves to Phase III.^[2]

Phase III trials involve even larger groups, often thousands of participants across multiple centers and sometimes multiple countries. These studies compare the new treatment to the current standard of care or a placebo. Phase III trials provide the definitive evidence needed for regulatory agencies like the U.S. Food and Drug Administration or the European Medicines Agency to decide whether to approve the treatment for widespread use. These trials can last several years and collect extensive data on effectiveness, safety, and how the treatment performs in real-world conditions.^[2]

Promising Therapies Under Investigation

Several innovative approaches are currently being studied in clinical trials for multiple sclerosis. One area of intense research involves developing more convenient formulations of existing effective therapies, such as subcutaneous (under the skin) versions of medications that are currently given intravenously. This can make treatment easier and more accessible for patients.^[8]

Researchers are investigating whether certain vitamins and supplements might have disease-modifying effects. High-dose biotin, a B vitamin, has been studied for its potential to help remyelination—the process of repairing damaged myelin sheaths around nerves. Early trial results have been mixed, with some studies showing possible benefits for progressive forms of MS, though larger confirmatory studies are needed. Alpha-lipoic acid, an antioxidant, is being studied for its potential neuroprotective effects. Clemastine, an antihistamine medication that has been available for decades, is being repurposed and tested for its potential to promote myelin repair.^[15]

Novel immunomodulatory agents with different mechanisms of action are in various stages of development. Some work by targeting specific pathways involved in inflammation without broadly suppressing the immune system, potentially offering a better balance between effectiveness and safety. Others aim to promote immune tolerance, essentially retraining the immune system to stop attacking myelin.^[8]

Neuroprotective therapies represent an exciting frontier in MS research. Rather than focusing solely on controlling the immune attack, these treatments aim to protect nerve cells from damage and support their survival even in an inflammatory environment. If successful, neuroprotective strategies could complement existing immune therapies to provide more comprehensive disease control.^[8]

Stem Cell Transplantation

Hematopoietic stem cell transplantation, also called bone marrow transplant or HSCT, is an intensive treatment approach being studied for aggressive MS that has not responded to conventional therapies. The procedure involves harvesting stem cells from the patient’s own blood or bone marrow, then using high-dose chemotherapy to essentially “reset” the immune system by eliminating existing immune cells. The harvested stem cells are then returned to the patient, where they regenerate a new immune system. Early results from clinical trials have been encouraging, showing that HSCT can lead to prolonged periods without disease activity in carefully selected patients. However, the treatment carries significant risks, including serious infections during the period when the immune system is being rebuilt. For this reason, stem cell transplantation is currently recommended only within clinical trials or for people with very aggressive MS who have not responded to other treatments.^[17]

Eligibility and Locations

Clinical trials for MS are being conducted worldwide, including in the United States, Europe, and many other countries. Each trial has specific eligibility criteria based on factors such as the type of MS, disease duration, previous treatments tried, age, and overall health status. Some trials seek participants who are newly diagnosed and have not yet started treatment, while others look for people with progressive forms of MS or those who have not responded adequately to currently available medications. Trial information, including locations and how to inquire about participation, is typically available through MS advocacy organizations, hospital research programs, and online registries of clinical studies.^[6]

Most Common Treatment Methods

• Injectable disease-modifying therapies
  • Interferon beta preparations (interferon beta-1a and interferon beta-1b) given under the skin or into muscle to modulate immune response and reduce inflammation
  • Glatiramer acetate, a synthetic protein resembling myelin, administered as daily or three-times-weekly injections to divert immune attack
  • Anti-CD20 monoclonal antibodies such as ocrelizumab given by intravenous infusion every six months to selectively deplete B cells
  • Natalizumab administered by intravenous infusion monthly to prevent immune cells from crossing into the central nervous system
• Oral disease-modifying medications
  • Teriflunomide taken once daily to prevent rapid immune cell multiplication
  • Dimethyl fumarate to protect nerve cells from oxidative stress and inflammation
  • Fingolimod that traps immune cells in lymph nodes preventing them from reaching the brain and spinal cord
• High-dose corticosteroid therapy for relapses
  • Methylprednisolone given intravenously over three to five days to reduce inflammation during acute exacerbations
  • High-dose oral steroid regimens as an alternative to intravenous treatment
• Symptom management treatments
  • Muscle relaxants including baclofen and tizanidine for spasticity and stiffness
  • Botulinum toxin injections for severe, localized muscle spasms
  • Anticonvulsant medications such as gabapentin and pregabalin for nerve pain
  • Antidepressant medications and cognitive behavioral therapy for mood disorders
  • Various medications for bladder control and bowel function
• Rehabilitation therapies
  • Physical therapy to improve strength, balance, and mobility
  • Occupational therapy to maintain independence in daily activities
  • Cognitive rehabilitation to address memory and thinking challenges
• Immunosuppressive therapy
  • Mitoxantrone for aggressive or worsening forms of MS, with use limited by cumulative dose toxicity